May 18, 2020 / 08:30PM GMT
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the AB-729 Clinical Update. (Operator Instructions) Please be advised that today's conference call is being recorded. (Operator Instructions)
I would -- at this time, I would like to hand the conference over to Ms. Pam Murphy. Thank you. Ma'am, please go ahead.
Pam Murphy - Arbutus Biopharma Corporation - IR Consultant
Good afternoon. And hopefully, everyone has been able to connect to the AB-729 clinical update webcast, and that you are able to access the slides. With me today from the Arbutus executive team are Bill Collier, President and Chief Executive Officer; Dr. Gaston Picchio, Chief Development Officer; Dr. Mike Sofia, Chief Scientific Officer; and Dave Hastings, Chief Financial Officer. Bill will begin with a quick summary of the data and planned next steps for AB-729. Gaston will then walk you through the additional positive clinical data for AB-729 described in today's press release. After Gaston's presentation, we'll then open up the call for Q&A.
Before we begin,
Arbutus Biopharma Corp AB-729 Clinical Update Conference Call Transcript
May 19, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers